Allogene Therapeutics, Inc. - ALLO STOCK NEWS

Allogene Therapeutics has announced promising preclinical results for its AlloCAR T™ candidate, ALLO-213, targeting DLL3 in small cell lung cancer (SCLC). Published in Clinical Cancer Research, the study highlights that ALLO-213 effectively controls tumor growth while exhibiting no off-tumor toxicity. SCLC is a highly aggressive cancer with limited therapies, affecting about 30,000 patients annually in the U.S., and has a 5-year survival rate of only 7%. This development positions Allogene favorably in the expanding field of allogeneic CAR T therapies, particularly for challenging solid tumors.

ALLO-715, an allogeneic anti-BCMA CAR T candidate, has shown promising results in the Phase 1 UNIVERSAL trial for relapsed/refractory multiple myeloma, as reported in Nature Medicine. This trial is the first to document significant therapeutic responses from a single dose of an allogeneic CAR T therapy. The initial data from 48 heavily pretreated patients show response rates comparable to established autologous CAR T therapies. The safety profile is manageable, with 92% of patients treated and all products meeting specifications, suggesting a potential shift toward off-the-shelf cell therapies, improving accessibility for patients. Next steps include advancing the trial to Phase 2.

Allogene Therapeutics (Nasdaq: ALLO) announced its participation in two investor conferences in January and February 2023. The company will attend the B. Riley Securities’ 3rd Annual Oncology Conference on January 18, 2023, at 7:00 AM PT and the 5th Annual Guggenheim Oncology Days on February 9, 2023, at 6:35 AM PT. Webcasts from these events will be available on the company's website, allowing for replay for 30 days. Allogene is developing allogeneic CAR T cell therapies, aiming to provide more accessible cancer treatments. For updates, visit www.allogene.com.

Allogene Therapeutics, a clinical-stage biotechnology company focused on allogeneic CAR T therapies, announced that Dr. David Chang will present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 3:45 p.m. PT, in San Francisco. The presentation will be accessible via a live audio webcast on the company’s website, followed by a replay available for 30 days. Allogene is committed to advancing cell therapy to make it more accessible and reliable for patients.

Allogene Therapeutics announced the appointment of Zachary J. Roberts, M.D., Ph.D., as Executive Vice President of Research and Development. This key leadership change follows the resignation of Rafael Amado, M.D. Dr. Roberts brings extensive experience from Instil Bio and Kite Pharma, where he played a crucial role in developing CAR T therapies. Allogene aims to expedite its pipeline, highlighted by recent positive clinical data for its AlloCAR T candidates like ALLO-501A for large B cell lymphoma. The company is set to initiate pivotal trials in 2023, including the EXPAND and ALPHA2 trials.

Allogene Therapeutics, Inc. (Nasdaq: ALLO) presented promising updates on its allogeneic CAR T programs at a recent R&D showcase. The lead CD19 program, ALLO-501A, showed a 67% overall response rate and a 58% complete response rate in relapsed/refractory large B cell lymphoma, with durable results for over 26 months. In the BCMA program, ALLO-715 demonstrated similar efficacy in multiple myeloma, achieving a 67% overall response rate. The company also introduced its Dagger™ technology aimed at enhancing CAR T cell persistence. Initial data from the solid tumor candidate, ALLO-316, indicated a 100% disease control rate in CD70 positive renal cell carcinoma.

Allogene Therapeutics (Nasdaq: ALLO) recently showcased promising preclinical data on a one-step gene editing strategy designed to prevent the rejection of AlloCAR T™ cells by host immune cells. This approach demonstrated its superiority over B2M knockout in a syngeneic in vivo model. The proprietary technology aims to enhance the effectiveness of off-the-shelf CAR T therapies by cloaking these cells from both T and NK cells. This research was presented at the 37th Annual Meeting of the Society for Immunotherapy of Cancer.

Allogene Therapeutics (Nasdaq: ALLO) will host a Research & Development Showcase on November 29, 2022, to discuss its CD19 and BCMA programs. The hybrid event will occur at 10:00 AM PT in New York, with limited in-person attendance. Registration is required. Additionally, Allogene will participate in five investor conferences starting with the Cowen 6th Annual IO Next Summit on November 11, 2022. Webcasts will be available on the company’s website for those unable to attend.

Allogene Therapeutics announced promising results from its Phase 1 UNIVERSAL trial of ALLO-715, an allogeneic CAR T product for multiple myeloma, demonstrating significant responses. The updated data, including safety and efficacy results from lymphodepletion, will be presented at the American Society of Hematology meeting from December 10-13, 2022. The company will also host a Research & Development Showcase on November 29, 2022, to discuss further plans and insights regarding ALLO-715.